Rathbones Group PLC Acquires 24,314 Shares of DexCom, Inc. (NASDAQ:DXCM)

Rathbones Group PLC grew its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,159,013 shares of the medical device company's stock after buying an additional 24,314 shares during the period. Rathbones Group PLC owned approximately 0.30% of DexCom worth $90,136,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Forvis Mazars Wealth Advisors LLC increased its holdings in shares of DexCom by 0.7% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after acquiring an additional 118 shares in the last quarter. Principal Securities Inc. increased its stake in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after purchasing an additional 135 shares in the last quarter. Larson Financial Group LLC raised its holdings in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the period. Level Four Advisory Services LLC lifted its stake in DexCom by 1.1% in the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after buying an additional 150 shares in the last quarter. Finally, TD Private Client Wealth LLC boosted its holdings in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after buying an additional 167 shares during the period. Institutional investors own 97.75% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and lifted their price target for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Finally, Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and an average target price of $99.00.

Insider Buying and Selling at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock worth $8,044,178 over the last ninety days. Insiders own 0.30% of the company's stock.

DexCom Stock Performance

NASDAQ DXCM traded down $1.16 during trading on Friday, reaching $66.14. 4,787,867 shares of the company's stock were exchanged, compared to its average volume of 4,188,339. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business has a 50 day moving average price of $76.92 and a 200-day moving average price of $76.62. The stock has a market capitalization of $25.93 billion, a P/E ratio of 46.25, a PEG ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $139.24.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.